Cargando…

Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy

PURPOSE: Metabolic changes upon antiangiogenic therapy of recurrent glioblastomas (rGBMs) may provide new biomarkers for treatment efficacy. Since in vitro models showed that phospholipid membrane metabolism provides specific information on tumor growth we employed in-vivo MR-spectroscopic imaging (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattingen, Elke, Bähr, Oliver, Rieger, Johannes, Blasel, Stella, Steinbach, Joachim, Pilatus, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592858/ https://www.ncbi.nlm.nih.gov/pubmed/23520454 http://dx.doi.org/10.1371/journal.pone.0056439

Ejemplares similares

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study
por: Steidl, Eike, et al.
Publicado: (2016)

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
por: RIEGER, JOHANNES, et al.
Publicado: (2014)

Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma
por: Thiepold, Anna-Luisa, et al.
Publicado: (2015)

Proton 1H- and Phosphorus 31P-MR spectroscopy (MRS) in asymptomatic HIV-positive patients
por: Schuettfort, Gundolf, et al.
Publicado: (2014)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Non-Invasive Measurement of Drug and 2-HG Signals Using (19)F and (1)H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
por: Wenger, Katharina J., et al.
Publicado: (2020)

Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial
por: Wenger, Katharina J., et al.
Publicado: (2020)

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy
por: Maurer, Gabriele D, et al.
Publicado: (2011)

Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBV(max) nor vessel densities correlate between newly diagnosed and progressive glioblastoma
por: Steidl, Eike, et al.
Publicado: (2023)

New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
por: Zeiner, Pia S., et al.
Publicado: (2019)

SMART: physical activity and cerebral metabolism in older people: study protocol for a randomised controlled trial
por: Fleckenstein, Johannes, et al.
Publicado: (2015)

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
por: Beal, Kathryn, et al.
Publicado: (2011)

Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma
por: Maurer, Gabriele D., et al.
Publicado: (2021)

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
por: Divé, Iris, et al.
Publicado: (2023)

Impaired oxygen extraction and adaptation of intracellular energy metabolism in cerebral small vessel disease
por: Reiländer, Annemarie, et al.
Publicado: (2023)

The Bioenergetic Status Relates to Dopamine Neuron Loss in Familial PD with PINK1 Mutations
por: Hilker, Rüediger, et al.
Publicado: (2012)

Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis
por: Lim, Haet Nim, et al.
Publicado: (2018)

Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy
por: Skolnik, Aaron D., et al.
Publicado: (2018)

Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme
por: Kochar, Arshneel Singh, et al.
Publicado: (2018)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature
por: Khattab, Mohamed H., et al.
Publicado: (2015)

In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma
por: Senrung, Anna, et al.
Publicado: (2023)

Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
por: Shirai, Katsuyuki, et al.
Publicado: (2012)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
por: Chinot, Olivier L., et al.
Publicado: (2013)

Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma
por: de Groot, John, et al.
Publicado: (2012)

Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
por: Clavreul, Anne, et al.
Publicado: (2019)

Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
por: Stadlbauer, Andreas, et al.
Publicado: (2017)

Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations
por: Nery de Albuquerque Rego, Gabriel, et al.
Publicado: (2020)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH
por: Slavc, Irene, et al.
Publicado: (2020)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma
por: Angara, Kartik, et al.
Publicado: (2018)

Nanoformulation Shows Cytotoxicity against Glioblastoma Cell Lines and Antiangiogenic Activity in Chicken Chorioallantoic Membrane
por: Dallemole, Danieli Rosane, et al.
Publicado: (2021)

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
por: Burger, Michael C, et al.
Publicado: (2023)

Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
por: Privitera, Giuseppe, et al.
Publicado: (2009)

Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma
por: Müller, Andreas, et al.
Publicado: (2016)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0qbvltmk4807oc3e5eltlpbs5e